Navigation Links
TrialNetworks Co-founder and Chairman Vivek Murthy, MD, MBA, Nominated by President Barack Obama as Surgeon General of the United States of America

Needham, MA (PRWEB) November 15, 2013

TrialNetworks Co-founder and Chairman Vivek Murthy, MD, MBA, has been nominated to serve as the 19th Surgeon General of the United States of America by President Barack Obama.

Dr. Murthy is currently an attending physician at Brigham and Women’s Hospital and an instructor at Harvard Medical School. In 2011, President Obama appointed Dr. Murthy to the Advisory Group on Prevention, Health Promotion, and Integrative and Public Health. His past research has focused on the participation of women and minorities in cancer clinical trials, and his writings and research have been published in Science, Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute, and The Washington Post.

Based on his lifelong commitment to patient wellness and his conviction that modern technology can be used to enhance collaboration among clinical researchers to accelerate drug discovery, Dr. Murthy co-founded TrialNetworks with CEO Eric Silberstein (his Harvard University classmate) and CTO Ezra Freedman.

“Dr. Murthy’s focus has always been on using his experience in medicine and science to find ways to help patients and improve healthcare on a broad scale,” said Silberstein. “His vision and insights led to the creation of TrialNetworks and our Clinical Trial Optimization System, which enables pharmaceutical companies to bring novel therapies to patients faster by running more efficient and higher-quality trials. It is exciting and an honor that Dr. Murthy will now have such a public platform to share and apply his expertise to benefit the health and wellness of individuals across our nation.”

TrialNetworks customers and clinical operations executives who know Dr. Murthy agree.

“Having worked with TrialNetworks for years, Dr. Murthy’s passion for improving the clinical research process is inspiring,” said Dr. Murray Abramson, MD, MPH, Vice President of Global Clinical Operations at Biogen Idec. “As a study sponsor and drug developer, I appreciate how TrialNetworks invests in its customer relationships and partners with us to create innovative technology that helps solve our clinical operational challenges. We wish him the best of luck in his new post.”

Upon confirmation by the U.S. Senate, Dr. Murthy will step down as Chairman of TrialNetworks.

Added Silberstein, “On behalf of TrialNetworks and our customers, I would like to thank Dr. Murthy for his years of guidance and friendship and congratulate him on this well-earned and honored nomination as America’s Doctor.”

About TrialNetworks
TrialNetworks provides sponsors and CROs the industry's only Clinical Trial Optimization System. Using this modern and intuitive technology, customers such as Merck & Co. and Infinity Pharmaceuticals are able to transform the quality and efficiency of clinical operations at each stage of a trial from feasibility through closeout. TrialNetworks apps, including Checklist™, Training™, Document Library™, Visit Guide™, Action Items™ and Directory™, are available in a unified and secure cloud-based interface. Customers ranging from biotechs to Top-10 pharma companies have implemented the TrialNetworks platform for use in Phase I-IV trials by more than 25,000 site staff in 60 countries. To learn why sponsors and CROs rely on TrialNetworks to optimize clinical trial operations, request a guided online demo at

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. TrialNetworks Customer to Present Results of Using Site Engagement Technology to Improve Study Operations and Patient Enrollment at Clinical Trial Optimization Conference
2. TrialNetworks Feasibility Survey™ App Gets ARIAD Pharmaceuticals Unprecedented 75% Response from Potential Clinical Trial Investigator Sites
3. TrialNetworks Sees Strong Growth in Demand for its Clinical Trial Optimization System as Pharma Seeks Technology to Improve Operations Quality and Efficiency
4. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
5. AMS Co-Founder John Hauser Receives Lifetime Achievement Award
6. InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
7. Fate Therapeutics Announces the Appointment of William H. Rastetter as Chairman of its Board of Directors and Interim CEO
8. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
9. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
10. Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEO
11. PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium
Post Your Comments:
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
Breaking Biology Technology:
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
Breaking Biology News(10 mins):